163 related articles for article (PubMed ID: 38449509)
41. Correlation between tumor oxygenation and 18F-fluoromisonidazole PET data simulated based on microvessel images.
Mönnich D; Troost EG; Kaanders JH; Oyen WJ; Alber M; Zips D; Thorwarth D
Acta Oncol; 2013 Oct; 52(7):1308-13. PubMed ID: 23984808
[TBL] [Abstract][Full Text] [Related]
42. Correlation of biological aggressiveness assessed by 11C-methionine PET and hypoxic burden assessed by 18F-fluoromisonidazole PET in newly diagnosed glioblastoma.
Kawai N; Maeda Y; Kudomi N; Miyake K; Okada M; Yamamoto Y; Nishiyama Y; Tamiya T
Eur J Nucl Med Mol Imaging; 2011 Mar; 38(3):441-50. PubMed ID: 21072512
[TBL] [Abstract][Full Text] [Related]
43. Correlation between tumour biology status measured in triple-tracer 18F-fluorodeoxyglucose-18F-fluorothymidine- 18F-fluoromisonidazole-PET/CT study and human papillomavirus status in patients with head and neck cancer.
Cegla P; Joanna K; Sebastian G; Julian M; Michal S; Witold C
Nucl Med Commun; 2019 Jul; 40(7):752-757. PubMed ID: 30925543
[TBL] [Abstract][Full Text] [Related]
44. Combined uptake of [18F]FDG and [18F]FMISO correlates with radiation therapy outcome in head-and-neck cancer patients.
Thorwarth D; Eschmann SM; Holzner F; Paulsen F; Alber M
Radiother Oncol; 2006 Aug; 80(2):151-6. PubMed ID: 16920211
[TBL] [Abstract][Full Text] [Related]
45. [18F] fluoromisonidazole and [18F] fluorodeoxyglucose positron emission tomography in response evaluation after chemo-/radiotherapy of non-small-cell lung cancer: a feasibility study.
Gagel B; Reinartz P; Demirel C; Kaiser HJ; Zimny M; Piroth M; Pinkawa M; Stanzel S; Asadpour B; Hamacher K; Coenen HH; Buell U; Eble MJ
BMC Cancer; 2006 Mar; 6():51. PubMed ID: 16515707
[TBL] [Abstract][Full Text] [Related]
46. Prevalence of hypoxia and correlation with glycolytic metabolism and angiogenic biomarkers in metastatic colorectal carcinoma.
Lee ST; Muralidharan V; Tebbutt N; Wong P; Fang C; Liu Z; Gan H; Sachinidis J; Pathmaraj K; Christophi C; Scott AM
Eur J Nucl Med Mol Imaging; 2021 May; 48(5):1585-1592. PubMed ID: 33125527
[TBL] [Abstract][Full Text] [Related]
47. [
Tanguy J; Goirand F; Bouchard A; Frenay J; Moreau M; Mothes C; Oudot A; Helbling A; Guillemin M; Bonniaud P; Cochet A; Collin B; Bellaye PS
Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3058-3074. PubMed ID: 33580818
[TBL] [Abstract][Full Text] [Related]
48. Interobserver agreement of qualitative analysis and tumor delineation of 18F-fluoromisonidazole and 3'-deoxy-3'-18F-fluorothymidine PET images in lung cancer.
Thureau S; Chaumet-Riffaud P; Modzelewski R; Fernandez P; Tessonnier L; Vervueren L; Cachin F; Berriolo-Riedinger A; Olivier P; Kolesnikov-Gauthier H; Blagosklonov O; Bridji B; Devillers A; Collombier L; Courbon F; Gremillet E; Houzard C; Caignon JM; Roux J; Aide N; Brenot-Rossi I; Doyeux K; Dubray B; Vera P
J Nucl Med; 2013 Sep; 54(9):1543-50. PubMed ID: 23918733
[TBL] [Abstract][Full Text] [Related]
49. Correlation between ¹⁸F-fluoromisonidazole PET and expression of HIF-1α and VEGF in newly diagnosed and recurrent malignant gliomas.
Kawai N; Lin W; Cao WD; Ogawa D; Miyake K; Haba R; Maeda Y; Yamamoto Y; Nishiyama Y; Tamiya T
Eur J Nucl Med Mol Imaging; 2014 Oct; 41(10):1870-8. PubMed ID: 24781871
[TBL] [Abstract][Full Text] [Related]
50. Equivalent uniform aerobic dose in radiotherapy for hypoxic tumors.
Chvetsov AV; Muzi M
Phys Med Biol; 2024 Apr; 69(8):. PubMed ID: 38457839
[No Abstract] [Full Text] [Related]
51. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
52. Usefulness of FMISO-PET for glioma analysis.
Kobayashi H; Hirata K; Yamaguchi S; Terasaka S; Shiga T; Houkin K
Neurol Med Chir (Tokyo); 2013; 53(11):773-8. PubMed ID: 24172591
[TBL] [Abstract][Full Text] [Related]
53. Complementary but distinct roles for MRI and 18F-fluoromisonidazole PET in the assessment of human glioblastomas.
Swanson KR; Chakraborty G; Wang CH; Rockne R; Harpold HL; Muzi M; Adamsen TC; Krohn KA; Spence AM
J Nucl Med; 2009 Jan; 50(1):36-44. PubMed ID: 19091885
[TBL] [Abstract][Full Text] [Related]
54. pO(2) Polarography versus positron emission tomography ([(18)F] fluoromisonidazole, [(18)F]-2-fluoro-2'-deoxyglucose). An appraisal of radiotherapeutically relevant hypoxia.
Gagel B; Reinartz P; Dimartino E; Zimny M; Pinkawa M; Maneschi P; Stanzel S; Hamacher K; Coenen HH; Westhofen M; Büll U; Eble MJ
Strahlenther Onkol; 2004 Oct; 180(10):616-22. PubMed ID: 15480509
[TBL] [Abstract][Full Text] [Related]
55. Evaluation of Optimal Post-Injection Timing of Hypoxic Imaging with
Kawamura M; Yoshimura M; Shimizu Y; Sano K; Ishimori T; Nakamoto Y; Mizowaki T; Hiraoka M
Mol Imaging Biol; 2021 Aug; 23(4):597-603. PubMed ID: 33475945
[TBL] [Abstract][Full Text] [Related]
56. Lack of concordance between the F-18 fluoromisonidazole PET and the F-18 FDG PET in human glioblastoma.
De Clermont H; Huchet A; Lamare F; Rivière A; Fernandez P
Clin Nucl Med; 2011 Dec; 36(12):e194-5. PubMed ID: 22064107
[No Abstract] [Full Text] [Related]
57. Influence of the scan time point when assessing hypoxia in
Kobayashi K; Manabe O; Hirata K; Yamaguchi S; Kobayashi H; Terasaka S; Toyonaga T; Furuya S; Magota K; Kuge Y; Kudo K; Shiga T; Tamaki N
Eur J Nucl Med Mol Imaging; 2020 Jul; 47(8):1833-1842. PubMed ID: 31781832
[TBL] [Abstract][Full Text] [Related]
58. Imaging hypoxia after oxygenation-modification: comparing [18F]FMISO autoradiography with pimonidazole immunohistochemistry in human xenograft tumors.
Troost EG; Laverman P; Kaanders JH; Philippens M; Lok J; Oyen WJ; van der Kogel AJ; Boerman OC; Bussink J
Radiother Oncol; 2006 Aug; 80(2):157-64. PubMed ID: 16905213
[TBL] [Abstract][Full Text] [Related]
59. Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) positron emission tomography: Comparative study featuring microPET imaging, Po2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models.
O'Donoghue JA; Zanzonico P; Pugachev A; Wen B; Smith-Jones P; Cai S; Burnazi E; Finn RD; Burgman P; Ruan S; Lewis JS; Welch MJ; Ling CC; Humm JL
Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1493-502. PubMed ID: 15817355
[TBL] [Abstract][Full Text] [Related]
60. Baseline [(18)F]FMISO μPET as a Predictive Biomarker for Response to HIF-1α Inhibition Combined with 5-FU Chemotherapy in a Human Colorectal Cancer Xenograft Model.
De Bruycker S; Vangestel C; Van den Wyngaert T; Wyffels L; Wouters A; Pauwels P; Staelens S; Stroobants S
Mol Imaging Biol; 2016 Aug; 18(4):606-16. PubMed ID: 26728163
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
